Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients

Status unconfirmed · Early Phase 1

Conditions studied: Esophageal Cancer

In brief

The purpose of this study is to demonstrate that orally administered itraconazole, a commonly used antifungal medication, can inhibit Hedgehog pathway signaling in patients with esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).

Key facts

Study ID

NCT02749513

Run by

Dallas VA Medical Center

People needed

18

Starts

2016-01-01

Expected to finish

2022-10-01

Last updated by the study team

2021-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer

You may not qualify if…

• Patients unwilling or unable to provide informed consent
• Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count <100,000/mm3, INR>1.5)
• Esophageal varices
• Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe participation in the study
• QTc>450 ms
• LFT's>3xULN
• Pregnancy
• Allergy to itraconazole
• History of symptomatic congestive heart failure

Where it is running

• Dallas VA Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.